ULTRESA CAPSULE (DELAYED RELEASE)

Држава: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

PROTEASE; AMYLASE; LIPASE

Доступно од:

APTALIS PHARMA CANADA ULC

АТЦ код:

A09AA02

INN (Међународно име):

MULTIENZYMES (LIPASE, PROTEASE ETC)

Дозирање:

88900UNIT; 98000UNIT; 23000UNIT

Фармацеутски облик:

CAPSULE (DELAYED RELEASE)

Састав:

PROTEASE 88900UNIT; AMYLASE 98000UNIT; LIPASE 23000UNIT

Пут администрације:

ORAL

Јединице у пакету:

100

Тип рецептора:

Prescription

Терапеутска област:

DIGESTANTS

Резиме производа:

Active ingredient group (AIG) number: 0302964035; AHFS:

Статус ауторизације:

APPROVED

Датум одобрења:

2000-06-08

Карактеристике производа

_ _
_ULTRESA_
_®_
_ – Pancrelipase Capsules _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 1 of 18 _
PRODUCT MONOGRAPH
PR
ULTRESA
®
(Pancrelipase USP)
Capsule (Delayed- Release)
13,800, 20,700 and 23,000 USP units of lipase
USP
Pancreatic enzymes
A09AA02
Aptalis Pharma Canada Inc.
597 Sir-Wilfrid-Laurier Blvd.
Mont-Saint-Hilaire, Québec
Canada J3H 6C4
Date of Approval:
June 05, 2015
Submission Control No: 173148
_ _
_ULTRESA_
_®_
_ – Pancrelipase Capsules _
_ _
_ _
_ _
_ _
_ _
_ _
_Page 2 of 18 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................8
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND STABILITY
..........................................................................................11
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................11
PART II: SCIENTIFIC INFORMATION
...............................................................................13
PHARMACEUTICAL INFORMATION
..........................................................................13
CLINIC